Processa Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Processa Pharmaceuticals generated cash of -$8,063,346, which is more than the previous year. Cash used in financing activities reached the amount of $6,268,724 last year. Net change in cash is therefore -$1,797,398.
Cash Flow
| 2014 | -2.69M | -44.94K | 2.57M |
|---|---|---|---|
| 2015 | -871.90K | 40.20K | 821.09K |
| 2016 | -43.20K | 17K | 15K |
| 2017 | -1.65M | 1.00M | 2.42M |
| 2018 | -3.70M | -22.28K | 2.62M |
| 2019 | -2.75M | 0 | 1.70M |
| 2020 | -3.14M | 0 | 17.86M |
| 2021 | -8.71M | 0 | 9.79M |
| 2022 | -9.60M | 0 | -388.84K |
| 2023 | -8.06M | -2.77K | 6.26M |
PCSA Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 6.50M | 16.49M | 15.41M | 691.53K | 1.74M | 2.84M | 1.07M | 14.44K | 25.04K | 186.86K |
Operating activities | ||||||||||
Net income | -11.12M | -27.42M | -11.42M | -14.41M | -3.35M | -3.76M | -1.85M | -337.17K | -2.98M | -4.52M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 222 | 788.49K | 790.97K | 803.77K | 803.77K | 630.09K | 1.86K | 159 | 238.82K | 461.26K |
Stock-based compensation expense | 1.06M | 8.82M | 3.40M | 2.73M | 510.47K | 0 | 0 | 6.69K | 96.92K | 231.52K |
| Deferred income tax benefit | 1.06M | 8.82M | 3.40M | 2.73M | 510.47K | 0 | 0 | 6.69K | 96.92K | 231.52K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 70.27K | 6.75K | -77.02K | 0 | 0 | 0 | 0 | 213.41K | -293.55K |
Inventories | 0 | -70.27K | -6.75K | 77.02K | 0 | 0 | 227.65K | -227.65K | -7.06K | -77.47K |
Accounts payable | -15.93K | 108.64K | -101.78K | 245.08K | -216.49K | 241.41K | 9.99K | -10.34K | 5.31K | 84.39K |
Cash generated by operating activities | -8.06M | -9.60M | -8.71M | -3.14M | -2.75M | -3.70M | -1.65M | -43.20K | -871.90K | -2.69M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -2.77K | 0 | 0 | 0 | 0 | -20.5K | -20.62K | -23.77K | -1.39K | -48.29K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | -1.78K | 6.28K | 17K | 31.1K | 3.35K |
Cash generated by investing activities | -2.77K | 0 | 0 | 0 | 0 | -22.28K | 1.00M | 17K | 40.20K | -44.94K |
Financing activities | ||||||||||
Common Stock Issued | 6.32M | 0 | 10.04M | 17.10M | 0 | 2.87M | 0 | 4.27M | 88K | 366.32K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | -388.84K | -64.39K | -95.21K | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | -862.45K | 805K | 0 | 2.58M | 0 | 733.09K | -545.52K |
Cash used in financing activities | 6.26M | -388.84K | 9.79M | 17.86M | 1.70M | 2.62M | 2.42M | 15K | 821.09K | 2.57M |
Net Change In Cash | -1.79M | -9.99M | 1.08M | 14.72M | -1.04M | -1.10M | 1.77M | -11.20K | -10.60K | -165.63K |
Cash at end of period | 4.70M | 6.50M | 16.49M | 15.41M | 691.53K | 1.74M | 2.84M | 3.23K | 14.44K | 21.23K |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |